Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis

Stopped Due to significantly slower than expected enrollment, the Sponsor decided to terminate the study.

Conditions

• Relapsing Remitting Multiple Sclerosis

Interventions

• DRUG: BG00002 (natalizumab)
• DRUG: interferon beta-1a
• DRUG: glatiramer acetate

Sponsor

Biogen

Collaborators

• [object Object]